166 related articles for article (PubMed ID: 29207143)
1. Screening and antitumor effect of an anti‑CTLA‑4 nanobody.
Wan R; Liu A; Hou X; Lai Z; Li J; Yang N; Tan J; Mo F; Hu Z; Yang X; Zhao Y; Lu X
Oncol Rep; 2018 Feb; 39(2):511-518. PubMed ID: 29207143
[TBL] [Abstract][Full Text] [Related]
2. Characterization and applications of Nanobodies against human procalcitonin selected from a novel naïve Nanobody phage display library.
Yan J; Wang P; Zhu M; Li G; Romão E; Xiong S; Wan Y
J Nanobiotechnology; 2015 May; 13():33. PubMed ID: 25944262
[TBL] [Abstract][Full Text] [Related]
3. Nanobody against PDL1.
Li S; Jiang K; Wang T; Zhang W; Shi M; Chen B; Hua Z
Biotechnol Lett; 2020 May; 42(5):727-736. PubMed ID: 32006351
[TBL] [Abstract][Full Text] [Related]
4. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G
J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
[TBL] [Abstract][Full Text] [Related]
5. Nanobody-based CTLA4 inhibitors for immune checkpoint blockade therapy of canine cancer patients.
Marable J; Ruiz D; Jaiswal AK; Bhattacharya R; Pantazes R; Agarwal P; Suryawanshi AS; Bedi D; Mishra A; Smith BF; Sandey M
Sci Rep; 2021 Oct; 11(1):20763. PubMed ID: 34675296
[TBL] [Abstract][Full Text] [Related]
6. High affinity nanobodies against human epidermal growth factor receptor selected on cells by E. coli display.
Salema V; Mañas C; Cerdán L; Piñero-Lambea C; Marín E; Roovers RC; Van Bergen En Henegouwen PM; Fernández LÁ
MAbs; 2016 Oct; 8(7):1286-1301. PubMed ID: 27472381
[TBL] [Abstract][Full Text] [Related]
7. Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.
Rausch J; Lopez PA; Bialojan A; Denny M; Langguth P; Probst HC; Schild H; Radsak MP
J Dermatol Sci; 2017 Sep; 87(3):300-306. PubMed ID: 28666747
[TBL] [Abstract][Full Text] [Related]
8. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
9. Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18.
Ma Z; Li W; Yoshiya S; Xu Y; Hata M; El-Darawish Y; Markova T; Yamanishi K; Yamanishi H; Tahara H; Tanaka Y; Okamura H
Clin Cancer Res; 2016 Jun; 22(12):2969-80. PubMed ID: 26755531
[TBL] [Abstract][Full Text] [Related]
10. Recombinant λ bacteriophage displaying nanobody towards third domain of HER-2 epitope inhibits proliferation of breast carcinoma SKBR-3 cell line.
Shoae-Hassani A; Mortazavi-Tabatabaei SA; Sharif S; Madadi S; Rezaei-Khaligh H; Verdi J
Arch Immunol Ther Exp (Warsz); 2013 Feb; 61(1):75-83. PubMed ID: 23224340
[TBL] [Abstract][Full Text] [Related]
11. Production and Characterization of Novel Camel Single Domain Antibody Targeting Mouse Vascular Endothelial Growth Factor.
Kazemi-Lomedasht F; Behdani M; Habibi-Anbouhi M; Shahbazzadeh D
Monoclon Antib Immunodiagn Immunother; 2016 Jun; 35(3):167-71. PubMed ID: 27167350
[TBL] [Abstract][Full Text] [Related]
12. Development of protective agent against Hottentotta saulcyi venom using camelid single-domain antibody.
Darvish M; Behdani M; Shokrgozar MA; Pooshang-Bagheri K; Shahbazzadeh D
Mol Immunol; 2015 Dec; 68(2 Pt B):412-20. PubMed ID: 26468036
[TBL] [Abstract][Full Text] [Related]
13. Isolation and characterization of nanobodies against epithelial cell adhesion molecule as novel theranostic agents for cancer therapy.
Roshan R; Naderi S; Behdani M; Cohan RA; Ghaderi H; Shokrgozar MA; Golkar M; Kazemi-Lomedasht F
Mol Immunol; 2021 Jan; 129():70-77. PubMed ID: 33183767
[TBL] [Abstract][Full Text] [Related]
14. Identification of Useful Nanobodies by Phage Display of Immune Single Domain Libraries Derived from Camelid Heavy Chain Antibodies.
Romao E; Morales-Yanez F; Hu Y; Crauwels M; De Pauw P; Hassanzadeh GG; Devoogdt N; Ackaert C; Vincke C; Muyldermans S
Curr Pharm Des; 2016; 22(43):6500-6518. PubMed ID: 27669966
[TBL] [Abstract][Full Text] [Related]
15. Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice.
Ahern E; Harjunpää H; Barkauskas D; Allen S; Takeda K; Yagita H; Wyld D; Dougall WC; Teng MWL; Smyth MJ
Clin Cancer Res; 2017 Oct; 23(19):5789-5801. PubMed ID: 28634284
[No Abstract] [Full Text] [Related]
16. Cytotoxic T lymphocyte antigen-4 blockade enhances antitumor immunity by stimulating melanoma-specific T-cell motility.
Pentcheva-Hoang T; Simpson TR; Montalvo-Ortiz W; Allison JP
Cancer Immunol Res; 2014 Oct; 2(10):970-80. PubMed ID: 25038199
[TBL] [Abstract][Full Text] [Related]
17. Developing and characterizing a single-domain antibody (nanobody) against human cytotoxic T-lymphocyte-associated protein 4 (hCTLA-4).
Sotoudeh N; Noormohammadi Z; Habibi-Anbouhi M; Kazemi-Lomedasht F; Behdani M
Iran J Basic Med Sci; 2021 Sep; 24(9):1264-1271. PubMed ID: 35083014
[TBL] [Abstract][Full Text] [Related]
18. Complete antitumor protection by perioperative immunization with GM3/VSSP vaccine in a preclinical mouse melanoma model.
Gabri MR; Mazorra Z; Ripoll GV; Mesa C; Fernandez LE; Gomez DE; Alonso DF
Clin Cancer Res; 2006 Dec; 12(23):7092-8. PubMed ID: 17145833
[TBL] [Abstract][Full Text] [Related]
19. A novel VHH nanobody against the active site (the CA domain) of tumor-associated, carbonic anhydrase isoform IX and its usefulness for cancer diagnosis.
Araste F; Ebrahimizadeh W; Rasooli I; Rajabibazl M; Mousavi Gargari SL
Biotechnol Lett; 2014 Jan; 36(1):21-8. PubMed ID: 24068505
[TBL] [Abstract][Full Text] [Related]
20. Joining the in vitro immunization of alpaca lymphocytes and phage display: rapid and cost effective pipeline for sdAb synthesis.
Comor L; Dolinska S; Bhide K; Pulzova L; Jiménez-Munguía I; Bencurova E; Flachbartova Z; Potocnakova L; Kanova E; Bhide M
Microb Cell Fact; 2017 Jan; 16(1):13. PubMed ID: 28114943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
